MedTrace Logo

Retrospective Analysis of Response Markers and Adverse Events in Melanoma Patients Treated With Pembrolizumab

NCT02600169 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 150

Last updated 2024-05-06

No results posted yet for this study

Summary

This study is a retrospective cohort study. A database will be created from the data available of all patients that have participate in the named patient program for pembrolizumab in the Netherlands. This database will be used for analysis of response markers and for an evaluation of adverse events.

Conditions

Interventions

DRUG

Pemprolizumab

All patients in this study have received treatment with pembrolizumab for the indication of an advanced melanoma.

Sponsors & Collaborators

  • University Medical Center Groningen

    lead OTHER

Principal Investigators

  • G.A.P. Hospers, MD, PhD · University Medical Center Groningen

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2015-07-31
Primary Completion
2019-04-30
Completion
2019-04-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02600169 on ClinicalTrials.gov